Abstract
Hypertension is a silent killer, with over half of affected adults unaware of their condition1,2. This lack of awareness is a major concern, as early intervention is critical for preventing major adverse cardiovascular events3,4. While cuffless wearable blood pressure (BP) monitors offer comfort and convenience, their reliance on periodic calibration and inconsistent accuracy have limited their clinical adoption5,6. Here we show that applying artificial intelligence (AI) pre-trained on almost 500,000 hours of data to multimodal waveforms (photoplethysmography and accelerometry) recorded using a widely available consumer smartwatch (AI-PPG-ACC-HTN), without any cuff calibration, can detect hypertension with accuracy levels comparable to traditional cuffed BP devices in the existing clinical framework, including both initial and confirmatory screening. We validated AI-PPG-ACC-HTN in a prospective, multicenter study of 196 diverse participants free from known cardiovascular disease and antihypertensive medication against gold-standard 24-hour ambulatory BP monitoring. Over seven days of real-world monitoring, AI-PPG-ACC-HTN detected hypertension with a sensitivity of 65.8% (95% CI, 54.0%-76.3%), specificity of 90.0% (83.2-94.7), and positive predictive value (PPV) of 80.6% (68.6-89.6). In comparison, initial office BP screening achieved a sensitivity of 55.3% (43.4-66.7), specificity of 90.0% (83.2-94.7) and PPV of 77.8% (64.4-88.0). For confirmatory testing of participants with elevated BP identified by initial office BP screening (N=48), AI-PPG-ACC-HTN detected hypertension with a sensitivity of 78.4% (61.8-90.2), specificity of 90.9% (58.7-99.8) and PPV of 96.7% (82.8-99.9). Comparatively, repeat office BP achieved a sensitivity of 67.6% (50.2-82.0), specificity of 63.6% (30.8-89.1) and PPV of 86.2% (68.3-96.1); multiday home BP monitoring achieved a sensitivity of 89.2% (74.6-97.0), specificity of 81.8% (48.2-97.7) and PPV of 94.3% (80.8-99.3). These results highlight an opportunity for consumer smartwatches to facilitate population-level opportunistic hypertension screening, offering an accessible tool to address this major public health challenge.
Competing Interest Statement
This study was funded by Alphabet Inc and/or a subsidiary thereof ('Alphabet'). P.D., L.C., J.Wu, M.G., B.D., J.Wang, U.K., H.K., A.P., M.M., S.P., J.B.S., P.R., M.T., and M.P. are employees of Alphabet and may own stock as part of the standard compensation.
Funding Statement
This study was funded by Alphabet Inc and/or a subsidiary thereof ('Alphabet').
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Quorum (now known as Advarra), Advarra (Columbia MD) and WCG Clinical Services (Puyallup WA) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Demographic information, mean BP readings across all modalities (office BPM, home BPM, ABPM) and AI-PPG-ACC-HTN scores and predictions for each participant from the prospective clinical study are made available. This research has been conducted using the UK Biobank Resource under Application Number 65275. Please visit the UK Biobank website, https://www.ukbiobank.ac.uk/, for application procedures. The AI-PPG-HTN scores for the UK Biobank PPG data will be returned to and made available via the UK Biobank.
